Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: A gynecologic oncology group study

David M. Gershenson, Anna M. Miller, Victoria Champion, Patrick Monahan, Qianqian Zhao, David Cella, Stephen D. Williams

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Purpose: To compare malignant ovarian germ cell tumor survivors with a matched control group of females on menstrual and reproductive outcomes, sexual functioning, and dyadic adjustment. Patients and Methods: Eligible patients met the following criteria: (1) history of malignant ovarian germ cell tumor; (2) treatment with surgery plus platinum-based chemotherapy; (3) age at least 18 years and continuously disease-free with minimum follow-up of 2 years; (4) capability of completing questionnaire and telephone interview; and (5) completion of written informed consent. The control group was drawn from acquaintances recommended by survivors and matched for age, race, and education. Scales with established reliability and validity were used to measure quality-of-life concepts of sexual functioning and social networks. Results: One hundred thirty-two survivors and 137 controls completed the study. Of 132 survivors, 71 (53.8%) had fertility-sparing surgery. Of fertile survivors, 62 (87.3%) reported still having menstrual periods. Twenty-four survivors reported 37 offspring after cancer treatment. Compared with controls, survivors had significantly greater reproductive concerns (P < .0001), less sexual pleasure (P = .003), and lower scores on the total Sexual Activity Scale Score (P = .001). However, survivors had better dyadic consensus (P = .004), dyadic satisfaction (P = .005), and dyadic cohesion (P = .014). Conclusion: Women who had fertility-sparing surgery were very likely to retain menstrual function and fertility after chemotherapy. Although there is some increase in gynecologic symptoms and diminution in sexual pleasure, survivors tended to have stronger, more positive relationships with significant others.

Original languageEnglish
Pages (from-to)2792-2797
Number of pages6
JournalJournal of Clinical Oncology
Volume25
Issue number19
DOIs
StatePublished - Jul 1 2007

Fingerprint

Germ Cell and Embryonal Neoplasms
Platinum
Survivors
Drug Therapy
Fertility
Pleasure
Social Adjustment
Control Groups
Informed Consent
Reproducibility of Results
Sexual Behavior
Social Support
Consensus
Research Design
Quality of Life
Interviews
Education
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors : A gynecologic oncology group study. / Gershenson, David M.; Miller, Anna M.; Champion, Victoria; Monahan, Patrick; Zhao, Qianqian; Cella, David; Williams, Stephen D.

In: Journal of Clinical Oncology, Vol. 25, No. 19, 01.07.2007, p. 2792-2797.

Research output: Contribution to journalArticle

@article{661e286ba9ba4fe6a072a7f05132acc3,
title = "Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: A gynecologic oncology group study",
abstract = "Purpose: To compare malignant ovarian germ cell tumor survivors with a matched control group of females on menstrual and reproductive outcomes, sexual functioning, and dyadic adjustment. Patients and Methods: Eligible patients met the following criteria: (1) history of malignant ovarian germ cell tumor; (2) treatment with surgery plus platinum-based chemotherapy; (3) age at least 18 years and continuously disease-free with minimum follow-up of 2 years; (4) capability of completing questionnaire and telephone interview; and (5) completion of written informed consent. The control group was drawn from acquaintances recommended by survivors and matched for age, race, and education. Scales with established reliability and validity were used to measure quality-of-life concepts of sexual functioning and social networks. Results: One hundred thirty-two survivors and 137 controls completed the study. Of 132 survivors, 71 (53.8{\%}) had fertility-sparing surgery. Of fertile survivors, 62 (87.3{\%}) reported still having menstrual periods. Twenty-four survivors reported 37 offspring after cancer treatment. Compared with controls, survivors had significantly greater reproductive concerns (P < .0001), less sexual pleasure (P = .003), and lower scores on the total Sexual Activity Scale Score (P = .001). However, survivors had better dyadic consensus (P = .004), dyadic satisfaction (P = .005), and dyadic cohesion (P = .014). Conclusion: Women who had fertility-sparing surgery were very likely to retain menstrual function and fertility after chemotherapy. Although there is some increase in gynecologic symptoms and diminution in sexual pleasure, survivors tended to have stronger, more positive relationships with significant others.",
author = "Gershenson, {David M.} and Miller, {Anna M.} and Victoria Champion and Patrick Monahan and Qianqian Zhao and David Cella and Williams, {Stephen D.}",
year = "2007",
month = "7",
day = "1",
doi = "10.1200/JCO.2006.08.4590",
language = "English",
volume = "25",
pages = "2792--2797",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "19",

}

TY - JOUR

T1 - Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors

T2 - A gynecologic oncology group study

AU - Gershenson, David M.

AU - Miller, Anna M.

AU - Champion, Victoria

AU - Monahan, Patrick

AU - Zhao, Qianqian

AU - Cella, David

AU - Williams, Stephen D.

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Purpose: To compare malignant ovarian germ cell tumor survivors with a matched control group of females on menstrual and reproductive outcomes, sexual functioning, and dyadic adjustment. Patients and Methods: Eligible patients met the following criteria: (1) history of malignant ovarian germ cell tumor; (2) treatment with surgery plus platinum-based chemotherapy; (3) age at least 18 years and continuously disease-free with minimum follow-up of 2 years; (4) capability of completing questionnaire and telephone interview; and (5) completion of written informed consent. The control group was drawn from acquaintances recommended by survivors and matched for age, race, and education. Scales with established reliability and validity were used to measure quality-of-life concepts of sexual functioning and social networks. Results: One hundred thirty-two survivors and 137 controls completed the study. Of 132 survivors, 71 (53.8%) had fertility-sparing surgery. Of fertile survivors, 62 (87.3%) reported still having menstrual periods. Twenty-four survivors reported 37 offspring after cancer treatment. Compared with controls, survivors had significantly greater reproductive concerns (P < .0001), less sexual pleasure (P = .003), and lower scores on the total Sexual Activity Scale Score (P = .001). However, survivors had better dyadic consensus (P = .004), dyadic satisfaction (P = .005), and dyadic cohesion (P = .014). Conclusion: Women who had fertility-sparing surgery were very likely to retain menstrual function and fertility after chemotherapy. Although there is some increase in gynecologic symptoms and diminution in sexual pleasure, survivors tended to have stronger, more positive relationships with significant others.

AB - Purpose: To compare malignant ovarian germ cell tumor survivors with a matched control group of females on menstrual and reproductive outcomes, sexual functioning, and dyadic adjustment. Patients and Methods: Eligible patients met the following criteria: (1) history of malignant ovarian germ cell tumor; (2) treatment with surgery plus platinum-based chemotherapy; (3) age at least 18 years and continuously disease-free with minimum follow-up of 2 years; (4) capability of completing questionnaire and telephone interview; and (5) completion of written informed consent. The control group was drawn from acquaintances recommended by survivors and matched for age, race, and education. Scales with established reliability and validity were used to measure quality-of-life concepts of sexual functioning and social networks. Results: One hundred thirty-two survivors and 137 controls completed the study. Of 132 survivors, 71 (53.8%) had fertility-sparing surgery. Of fertile survivors, 62 (87.3%) reported still having menstrual periods. Twenty-four survivors reported 37 offspring after cancer treatment. Compared with controls, survivors had significantly greater reproductive concerns (P < .0001), less sexual pleasure (P = .003), and lower scores on the total Sexual Activity Scale Score (P = .001). However, survivors had better dyadic consensus (P = .004), dyadic satisfaction (P = .005), and dyadic cohesion (P = .014). Conclusion: Women who had fertility-sparing surgery were very likely to retain menstrual function and fertility after chemotherapy. Although there is some increase in gynecologic symptoms and diminution in sexual pleasure, survivors tended to have stronger, more positive relationships with significant others.

UR - http://www.scopus.com/inward/record.url?scp=34447556890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447556890&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.08.4590

DO - 10.1200/JCO.2006.08.4590

M3 - Article

C2 - 17602084

AN - SCOPUS:34447556890

VL - 25

SP - 2792

EP - 2797

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 19

ER -